Wilmington Savings Fund Society FSB Purchases New Shares in Illumina, Inc. (NASDAQ:ILMN)

Wilmington Savings Fund Society FSB acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 5,917 shares of the life sciences company’s stock, valued at approximately $772,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Industrial Alliance Investment Management Inc. bought a new position in shares of Illumina during the 2nd quarter valued at approximately $34,000. TD Private Client Wealth LLC boosted its stake in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after buying an additional 141 shares during the period. Massmutual Trust Co. FSB ADV boosted its stake in Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after buying an additional 168 shares during the period. Private Trust Co. NA increased its position in Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after acquiring an additional 212 shares during the last quarter. Finally, Focused Wealth Management Inc purchased a new stake in shares of Illumina in the third quarter valued at $63,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on ILMN shares. Canaccord Genuity Group increased their price objective on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a research report on Tuesday, November 5th. TD Cowen raised their price target on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Stephens boosted their price objective on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. StockNews.com began coverage on Illumina in a research note on Thursday, August 29th. They issued a “buy” rating on the stock. Finally, Barclays boosted their target price on shares of Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $165.95.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $143.87 on Monday. The firm has a 50 day moving average of $144.27 and a 200 day moving average of $128.63. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The company has a market capitalization of $22.82 billion, a price-to-earnings ratio of -14.44 and a beta of 1.11. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same period in the previous year, the company posted $0.33 EPS. The business’s revenue for the quarter was down 3.5% compared to the same quarter last year. On average, sell-side analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.